SET-171

• Description:

  SET-171 is a JNK (c-Jun N-terminal kinase) inhibitor that exhibits significant anticancer activity and lipid metabolism regulation by inhibiting liver pyruvate kinase (PKL) expression. In anticancer studies, SET-171 shows IC50 values of 8.82 μM and 2.97 μM against HepG2 and Huh7 cell lines, respectively, indicating high cytotoxicity. Additionally, in non-alcoholic fatty liver disease (NAFLD) -related studies, SET-171 significantly reduces triacylglycerol (TAG) levels and inhibits the expression of steatosis-related proteins. SET-171 holds promise for research on hepatocellular carcinoma (HCC) and NAFLD[1].

• UNSPSC:

  12352005

• Target:

  JNK; Pyruvate Kinase

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway; Metabolic Enzyme/Protease

• Field of Research:

  Cancer; Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/set-171.html

• Smiles:

  BrC1=CC=CC(NC(CN2CCC3=C(SC(NC(C4=CC=CC5=C4C=CC=C5)=O)=C3C#N)C2)=O)=C1

• Molecular Formula:

  C27H21BrN4O2S

• Molecular Weight:

  545.45

• References & Citations:

  [1]Iqbal S, et al. Design and synthesis of novel JNK inhibitors targeting liver pyruvate kinase for the treatment of non-alcoholic fatty liver disease and hepatocellular carcinoma. Bioorg Chem. 2024 Jun;147:107425.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [3052985-32-4]